Literature DB >> 2286993

A clinical study of auriculotherapy in canine thoracolumbar disc disease.

J Still1.   

Abstract

Auriculotherapy (ear-point acupuncture) was used in dogs (n = 30) suffering from thoracolumbar disc disease, Types I-IV, with a duration of 1 to (47 means = 8) d. During auriculotherapy treatment, no analgaesics or antiinflammatory medications were used. Pressure-sensitive and electrically detectable points on the concave aspect of the external auricle were stimulated by insertion of stainless steel acupuncture needles for 20 min. One to 6 needles were used on each occasion in a maximum of 3 treatments. Fifty per cent of dogs recovered completely and 23% improved. Dogs with backpain only (Type I) and dogs with paresis (Type II) responded best with mean recovery times of 1.7 and 3.2 d respectively. The analgaesic effects were especially impressive. Auriculotherapy failed in 3 (50%) paralysed dogs (Types III and IV) in which post-mortem examinations confirmed focal myelitis and myelomalacia. Four of 12 dogs (33%) recorded relapsed in 1.4 to 26 weeks after successful treatment.

Entities:  

Mesh:

Year:  1990        PMID: 2286993

Source DB:  PubMed          Journal:  J S Afr Vet Assoc        ISSN: 1019-9128            Impact factor:   1.474


  3 in total

Review 1.  One Medicine, One Acupuncture.

Authors:  Narda G Robinson
Journal:  Animals (Basel)       Date:  2012-08-29       Impact factor: 2.752

2.  ACVIM consensus statement on diagnosis and management of acute canine thoracolumbar intervertebral disc extrusion.

Authors:  Natasha J Olby; Sarah A Moore; Brigitte Brisson; Joe Fenn; Thomas Flegel; Gregg Kortz; Melissa Lewis; Andrea Tipold
Journal:  J Vet Intern Med       Date:  2022-07-25       Impact factor: 3.175

3.  Simple acupoints prescription flow chart based on meridian theory: a retrospective study in 102 dogs.

Authors:  Jong-Ho Jeong; Joo-Young Song; Hyo-Gwon Jo; Ji-Min Kim; Samuel-S Yoon; Chul Park; Seunghyun Kim; Seong-Soo Roh; Bong Hyo Lee; Chae Ha Yang; Hee Young Kim
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-20       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.